Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by Golddetectoron Apr 15, 2022 3:49pm
300 Views
Post# 34606808

Reduvo updates April 14 2022 MD&A

Reduvo updates April 14 2022 MD&A

the update for Apr 14 MD&A. It looks like Reduvo approval is getting really close and they are working final details with HC. It looks like a done deal they even made advanced payment to manufacturers. A nr is expected soon.
"  As of the date of this MD&A, the Company has received information requests for updates to the product monograph, cardiovascular safety and drug abuse liability as well as its proposed pharmacovigilance plan. The Company is in discussions with Health Canada to address final commentary on the submission. REDUVOTM remains a top priority and the Company is ready to launch manufacturing activities as soon as possible following regulatory approval. Evidence of this is the advance paid by the Company to the manufacturing partner to secure production lots"

QIXLEEF updates is pretty much what Guy mentioned in his last interview.
 

Last time sp was to 50c when the application accepted by HC let's see where this din approval takes us.

gl to all longs only 

<< Previous
Bullboard Posts
Next >>